Ning Ma
11 Papers
6 Citations
Ning Ma is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
Ning Ma,Hui Qiao,Hanchuan Tao,Xinli Gan,Zhili Shan,Xiaomin Chen,Xiao-Jun Zhou +6 more
TL;DR: In this article , the authors evaluated treatment response, survival profile, and adverse events of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer (mGC) patients.
14
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
Masatoshi Kudo,Minshan Chen,Pierce K. H. Chow,Ahmed Kaseb,Han Chu Lee,Adam C. Yopp,Lars Becker,Bruno Kovic,Qinshu Lian,Ning Ma,Chun Wu,Shukui Qin,A. Chen +12 more
TL;DR: The IMbrave050 trial as mentioned in this paper showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) vs active surveillance in patients (pts) at high risk of HCC recurrence following resection or ablation with curative intent.
13
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
TL;DR: The combination of low-dose-intensity bevacizumab and weekly irinotecan was an effective and safe regimen for patients with platinum- and taxanes-resistant advanced epithelial ovarian cancer.
Abstract 1399: Discovery and development of PARP inhibitor senaparib
TL;DR: Senaparib is currently in several phase I/II, phase II and phase III clinical studies for the treatment of multiple tumor types either as single agent or in combination with temozolomide (TMZ).
5
A phase 1 dose‐escalation study of the poly(ADP‐ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors
Bo Gao,Mark Voskoboynik,Adam Cooper,Kate Wilkinson,Siao Nge Hoon,C-Y. Hsieh,Suixiong Cai,Ye Edward Tian,Jun Bao,Ning Ma,Chen Wang,Ming Zhang,Bao Lin Li,Mingchuan Guo,Ruiyu Zhou,Xiaozhu Wang,Cong Xu,Paul de Souza +17 more
TL;DR: Senaparib as discussed by the authors is a poly(ADP-ribose) polymerase-1/2 inhibitor with strong antitumor activity in preclinical studies and has been shown to be effective in patients with advanced solid tumors.
4